Clinical trials: Diabetes Type 2
Diabetes Mellitus, Type 2
A Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of night time low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 2 (NCT01435616)
- Testing
- Glargine, LY2605541
- Where
- 167 sites in United States, Argentina and 21 more
- Volunteers
- 1,538 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
A Phase 2 study Comparing the effects on glucose control of MEDI0382 in combination with Dapagliflozin and Metformin compared to placebo in combination with Dapagliflozin and Metformin in overweight/obese participants with Type 2…
- Trial name
- NCT03444584
- Testing
- MEDI0382, Dapaglifozin, Metformin
- Where
- 8 sites in Germany, Hungary and 1 more
- Volunteers
- 49 people
- Sponsor
- MedImmune LLC
Diabetes Mellitus, Insulin-Dependent
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes
The objective of this clinical trial is to investigate whether ladarixin has sufficient activity (preservation of β-cell function and slow-down of the progression of T1D) to warrant its further development (proof of concept…
- Trial name
- NCT02814838
- Testing
- Ladarixin
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 76 people
- Sponsor
- Dompé Farmaceutici S.p.A
Type 2 Diabetes Mellitus
Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II
Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes.
- Trial name
- TINSALT2D-II (NCT00799643)
- Testing
- Salsalate
- Where
- 21 sites in United States
- Volunteers
- 638 people
- Sponsor
- Joslin Diabetes Center
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in…
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Trial name
- SCORED (NCT03315143)
- Testing
- Sotagliflozin
- Where
- 754 sites in United States, Argentina and 43 more
- Volunteers
- 10,584 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes, Overweight
Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be…
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- NCT02014740
- Testing
- Liraglutide, Metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Diabetes Mellitus, Type 2
Digital Self-Management and Health Coaching for Type 2 Diabetes - Impact on Diabetes Clinical and Wellness Indicators
Each subject enrolled in the study will be requested to complete an intake questionnaire including diabetes quality of life questions.
- Trial name
- NCT04057248
- Testing
- Dario Blood Glucose Monitoring System, CDE
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- LabStyle Innovations Ltd.
Diabetes Mellitus, Type 2, Covid19
Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19
The COVID-19 pandemic has triggered extremely high hospitalization rates where mitigation strategies are urgently necessary to aid vulnerable Hispanic and Latino populations who are experiencing health disparities as well as high…
- Trial name
- NCT04591015
- Testing
- Hospital: DD-CA, Hospital: Usual Care (UC)
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Scripps Whittier Diabetes Institute
Diabetes Mellitus, Type 2
A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus
This study is designed to assess the safety, tolerability and pharmacodynamics of 6 weeks of oral doses of PF-05175157 provided as monotherapy in subjects with type 2 diabetes mellitus.
- Trial name
- NCT01792635
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Primary Objective: To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER 2 (NCT03371108)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 57 sites in United States
- Volunteers
- 567 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Psoriasis, Type 2 Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.
The primary purpose of this study is to determine if sitagliptin (Januvia®) improves psoriasis severity after 16 weeks of treatment in 20 participants with both psoriasis and type 2 diabetes mellitus.
- Trial name
- DIP (NCT01991197)
- Testing
- Sitagliptin, Gliclazide
- Where
- 2 sites in Ireland
- Volunteers
- 20 people
- Sponsor
- University College Dublin
Type 2 Diabetes Mellitus
Study of the Durability of Glycemic Control With Nateglinide
This multi-center, randomized controlled study aims to evaluate the durability and efficacy of nateglinide therapy for long term glycemic control compared with glimepiride.
- Trial name
- NCT00858013
- Testing
- Nateglinide, Glimepiride
- Where
- 7 sites in South Korea
- Volunteers
- 88 people
- Sponsor
- Ajou University School of Medicine
Diabetes Mellitus Non-insulin-dependent
The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)
to assess the effect of treatment with Sitagliptin (MK0431) on HbA1c (Hemoglobin A1c) and the safety and tolerability of Sitagliptin.
- Trial name
- NCT00832624
- Testing
- sitagliptin
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.
Insulin treatment often causes the blood glucose levels to fall too low. The body usually responds to low blood glucose levels by releasing hormones which act against the insulin to help correct the low blood glucose levels.
- Trial name
- NCT01194479
- Testing
- Formoterol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Yale University
Diabetes Mellitus, Type 2
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician.
- Trial name
- NCT02111096
- Testing
- LY2409021, Sitagliptin, Metformin
- Where
- 33 sites in United States, Greece and 2 more
- Volunteers
- 174 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type II
Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-Responders
The aim of the study is to develop a model that allows early identification of type-2 diabetic patients who will face progressive atherosclerosis despite intensive, multifactorial, target oriented treatment
- Trial name
- CARDIONOR (NCT00660790)
- Testing
- Intensified Treatment of risk factors
- Where
- Austria
- Volunteers
- 97 people
- Sponsor
- Medical University of Graz
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Effect of Diabetes Mellitus on Cholesterol Metabolism
HMG CoA reductase inhibitors (statins) are commonly used to treat high cholesterol (HC) in both type 1 and type 2 diabetes mellitus (DM).
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia
- Trial name
- NCT00879710
- Testing
- simvastatin or ezetimibe
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Medical College of Wisconsin
Type 2 Diabetes Mellitus, Healthy
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
The objective of this proposal is to provide quantitative dose-response data for effects of GLP-1 on myocardial glucose uptake in healthy control subjects and obese type 2 diabetic subjects, in support of the design of later…
- Trial name
- NCT01607450
- Testing
- GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Indiana University
Type 2 Diabetes Mellitus
An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial
Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005
- Trial name
- NCT00754624
- Testing
- Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
- Where
- 40 sites in United States, Bulgaria and 2 more
- Volunteers
- 229 people
- Sponsor
- Mannkind Corporation
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of the trial is to compare insulin detemir once daily to NPH insulin once daily as measured by blood sugar control in ageing subjects with type 2 diabetes naive to previous insulin…
- Trial name
- 3L (NCT00506662)
- Testing
- insulin detemir, insulin NPH
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 86 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.